EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

Carlo Signorelli iD, Maria Alessandra Calegari iD, Annunziato Anghelone, Alessandro Passardi iD, Giovanni Luca Frassineti iD, Alessandro Bittoni iD, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo iD, Cristina Morelli, Emanuela Dell'Aquila und 18 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31120574 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, 2024. Verfasst von Carlo Signorelli und 29 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy. Hauptthemen laut MEDLINE: Phenylurea Compounds, Colorectal Neoplasms, Trifluridine, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following the second line. Trifluridine/tipiracil (T) and regorafenib (R) have been the mainstay of therapy in this situation, as they both increased overall survival (OS) in comparison to a placebo. Despite the paucity of evidence, therapy rechallenge is also recognized as an option for practical use. In the third-line scenario of mCRC, we planned to investigate the survival outcomes using (T) and (R), both with and without prior rechallenge treatment. Materials and methods: Between 2012 and 2023, we examined the medical records of 1156 patients with refractory mCRC who were enrolled in the multicenter retrospective ReTrITA study. We then separated the patients into two cohorts based on the rechallenge therapy that was given before regorafenib and/or trifluridine/tipiracil at 17 Italian centres.

Results

A total of 981 patients underwent T and/or R therapy, while 175 patients had therapy rechallenge before T and/or R. The median overall survival (mOS) for patients treated with T/R and R/T sequences in the rechallenge therapy cohort was 14.5 months and 17.6 months, respectively (p = 0.1955). A statistically significant survival benefit was observed in patients who received monotheraphy with R (mOS: 6 months) compared to the T group (mOS: 4.2 months) (p = 0.0332). In the same cohort, a median progression-free survival (mPFS) benefit was demonstrated in favour of the R/T group (11.3 months) vs. 9 months of the reverse sequence (p = 0.4004). In the no-rechallenge cohort, the mOS was statistically longer in the R/T sequence than in the T/R sequence (16.2 months vs. 12.3 months, respectively; p = 0.0014). In terms of the mPFS, we saw the same significant result for the adoption of R/T treatment (11.5 months vs. 8.4 months, respectively; p < 0.0001). The two monotherapy groups did not reveal any significant differences.

Conclusions

This study suggests that rechallenge therapy may improve survival rates in the third-line treatment of mCRC, particularly if it is administered before sequential R/T treatment. This could allow for the extension of mCRC treatment choices until prospective studies are finished or randomised trials are performed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsColorectal NeoplasmsTrifluridinePyridinesThyminePyrrolidinesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedNeoplasm MetastasisAged, 80 and overDrug CombinationsAdultTreatment Outcome

Stichwörter der Autor:innen

metastatic colorectal cancerreal-world studyrechallenge therapyregorafenibthird-line therapytrifluridine/tipiracil

Substanzen

regorafenibPhenylurea CompoundsTrifluridinePyridinesThyminePyrrolidinestrifluridine tipiracil drug combinationDrug Combinations

Autor:innen und Institutionen

  • Medical Oncology Unit, Belcolle Hospital, ASL Viterbo, 01100 Viterbo, Italy.
  • Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, 00168 Rome, Italy.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Medical Oncology, "Vito Fazzi" Hospital, 73100 Lecce, Italy.
  • Medical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.

ORCID-Profile: Carlo Signorelli, Maria Alessandra Calegari, Alessandro Passardi, Giovanni Luca Frassineti, Alessandro Bittoni, Ina Valeria Zurlo, Giulia Arrivi, Fiorenza Santamaria

Zitieren

APA

Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Frassineti, G. L., Bittoni, A., Lucchetti, J., Angotti, L., Di Giacomo, E., Zurlo, I. V., Morelli, C., Dell'Aquila, E., Artemi, A., Gemma, D., Corsi, D. C., Emiliani, A., Ribelli, M., Mazzuca, F., Arrivi, G., …, & Basso, M. (2024). Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study. Current Oncology. https://doi.org/10.3390/curroncol31120574

Vancouver

Signorelli C, Calegari MA, Anghelone A, Passardi A, Frassineti GL, Bittoni A, et al. Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study. Current Oncology. 2024. doi:10.3390/curroncol31120574

BibTeX
@article{Signorelli2024,
  author = {Signorelli, Carlo and Calegari, Maria Alessandra and Anghelone, Annunziato and Passardi, Alessandro and Frassineti, Giovanni Luca and Bittoni, Alessandro and Lucchetti, Jessica and Angotti, Lorenzo and Di Giacomo, Emanuela and Zurlo, Ina Valeria and Morelli, Cristina and Dell'Aquila, Emanuela and Artemi, Adele and Gemma, Donatello and Corsi, Domenico Cristiano and Emiliani, Alessandra and Ribelli, Marta and Mazzuca, Federica and Arrivi, Giulia and Zoratto, Federica and Chilelli, Mario Giovanni and Schirripa, Marta and Morandi, Maria Grazia and Santamaria, Fiorenza and Dettori, Manuela and Cosimati, Antonella and Saltarelli, Rosa and Minelli, Alessandro and Lucci-Cordisco, Emanuela and Basso, Michele},
  title = {Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31120574}
}
Kostenlos starten →